Google
NEUP — NEUPHORIA THERAPEUTICS INC (Healthcare >> Biotechnology)
NEUP FAQ
What is NEUP's P/E ratio?
NEUPHORIA THERAPEUTICS INC (NEUP) currently trades at a P/E ratio of 9.10.
What is NEUP's ROE?
NEUPHORIA THERAPEUTICS INC reports a Return on Equity (ROE) of -93.64%.
What is NEUP's dividend yield?
NEUPHORIA THERAPEUTICS INC offers a dividend yield of 0.00%.
What is NEUP's Deepscope Quality Score?
Deepscope rates NEUP's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy NEUP?
Deepscope's AI Timing Score for NEUP is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does NEUP belong to?
NEUPHORIA THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 4.49
Price
-0.35
(-7.23%)
Day Change
|
|
|---|
NEUP, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Current growth of ROA was below our criteria.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is ok , ...
| Quality Factors |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 75 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 4.49 |
| PBV / Sector |
0.86 / 4.63
GREAT
|
| Earning Per Share | -4.87 |
| PE / Sector |
9.10 / 17.43
GREAT
|
| PEG or PE/Growth / Sector |
-113.70 / 0.53
|
| Average 1M Daily Value |
0.30 M
GREAT
|
| Average 1W Daily Value |
0.41 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:04 |
| Symbol | NEUP |
| Name | NEUPHORIA THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 5.40 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 25.40 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 100 Summit Drive, Burlington, MA, United States, 01803
Phone: 781 439 5551
Website: https://www.neuphoriatx.com
Sector: Healthcare >> Biotechnology
Description: Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; and Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
